Pre-emptive Short-term Nicotinamide Mononucleotide Treatment in a Mouse Model of Diabetic Nephropathy
The activation of NAD+-dependent deacetylase, Sirt1, by the administration of nicotinamide mononucleotide (NMN) ameliorates various aging-related diseases. Short-term NMN treatment mitigated mesangium expansion and foot process effacement. It also increased kidney concentrations of NAD+ and increased expression of Sirt1 and nicotinamide phosphoribosyltransferase (Nampt). Short-term NMN treatment in early-stage DN has remote renal protective effects.